Core Viewpoint - Kanglong Chemical (300759.SZ) reported a revenue of 14.095 billion yuan for 2025, representing a year-on-year growth of 14.82%. However, the net profit attributable to shareholders decreased by 7.22% to 1.664 billion yuan, while the net profit excluding non-recurring items increased by 38.85% to 1.538 billion yuan. The company also proposed a cash dividend of 2 yuan per 10 shares (tax included) [1] Financial Performance - The company's total revenue reached 14.095 billion yuan, marking a 14.82% increase year-on-year [1] - Net profit attributable to shareholders was 1.664 billion yuan, reflecting a decrease of 7.22% [1] - Net profit excluding non-recurring items was 1.538 billion yuan, showing a significant increase of 38.85% [1] - Basic earnings per share stood at 0.9443 yuan [1] Strategic Initiatives - The company emphasizes a customer-centric service philosophy and leverages a fully integrated service platform to meet diverse global client needs [1] - There has been a notable performance in business with large pharmaceutical clients, indicating successful strategic client expansion [1] - The company is actively expanding its customer base and utilizing advanced technologies to empower new drug development, maintaining industry leadership in small molecules while rapidly developing new molecular types [1] - In the Chinese market, the company is implementing market strategies tailored to local conditions, resulting in rapid growth in business with Chinese clients [1] - The new order amount signed in 2025 increased by over 14% year-on-year [1]

Core Insights - The company reported a revenue of 14.095 billion yuan for the year 2025, representing a year-on-year growth of 14.82% [1] - The net profit attributable to shareholders decreased by 7.22% to 1.664 billion yuan, while the net profit excluding non-recurring items increased by 38.85% to 1.538 billion yuan [1] - The basic earnings per share were 0.9443 yuan, and the company proposed a cash dividend of 2 yuan per 10 shares (tax included) [1] Business Strategy - The company emphasizes a customer-centric service philosophy and leverages an integrated service platform to meet diverse global client needs across different research and development stages [1] - Significant achievements were noted in expanding strategic client relationships, particularly with large pharmaceutical companies [1] - The company is actively enhancing its market strategies tailored to the Chinese market, resulting in rapid growth in client business within China [1] Market Performance - The company achieved a more than 14% year-on-year increase in new order amounts for 2025 [1] - The company maintains industry leadership in small molecule fields while also experiencing rapid development in new molecular type projects [1]

股票简称：百奥赛图 股票代码：688796 百奥赛图（北京）医药科技股份有限公司 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. （北京市大兴区中关村科技园区大兴生物医药产业基地宝参南街12号院） 首次公开发行股票科创板上市公告书 保荐机构（主承销商） 北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层 二〇二五年十二月九日 特别提示 百奥赛图（北京）医药科技股份有限公司（以下简称"百奥赛图"、"本公司"、 "发行人"或"公司"）股票将于 2025 年 12 月 10 日在上海证券交易所科创板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新股上市 初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 2 第一节 重要声明与提示 一、重要声明 本公司及全体董事、监事、高级管理人员保证上市公告书所披露信息的真实、准确、 完整，承诺上市公告书不存在虚假记载、误导性陈述或者重大遗漏，并依法承担法律责 任。 上海证券交易所、有关政府机关对本公司股票上市及有关事项的意见，均不表明对 本公司的任何保证。 本 公 司 提 醒 广 大 投 ...

Core Insights - The CXO industry appears to have emerged from a downturn in 2025, with notable profit growth among key players such as WuXi AppTec (89.06%), Hangzhou Tigermed Consulting (32.54%), and Kelun Pharmaceutical (15.83%) [2] - However, Tigermed stands out as the only major player in the CXO sector experiencing a decline, with a 29.61% year-on-year drop in Q1 2025 following a 79.99% decline in 2024 [2][3] Financial Performance - In Q1 2025, Tigermed reported revenue of 1.564 billion yuan, a decrease of 5.79% year-on-year, and a net profit of 165 million yuan, down 29.61% [3] - The gross margin fell from 37.83% in Q1 2024 to 30.03% in Q1 2025, indicating significant challenges in profitability [3] - For the full year 2024, Tigermed's revenue was 6.603 billion yuan, a decline of 10.58%, with net profit plummeting to 405 million yuan, a drop of 79.99% [4][7] Profitability Metrics - Tigermed's profitability has sharply declined, with gross margin decreasing from 47.43% in 2020 to 33.95% in 2024, and further to 30.03% in Q1 2025 [5] - The net profit margin also fell from 63.56% in 2020 to 6.78% in 2024, highlighting a severe reduction in profitability [5] Market Dynamics - The decline in Tigermed's performance is attributed to increased competition and a reduction in financing for innovative drug companies, which impacts order volumes [8][9] - In 2024, the domestic innovative drug financing dropped to approximately 4.2 billion USD, a nearly 20% decrease, affecting cash flow for many companies [9] Strategic Positioning - Tigermed operates as both a CRO service provider and an investment entity, which has created challenges during industry downturns [10] - As of the end of 2024, Tigermed held non-current financial assets worth 10.1 billion yuan, including equity investments in several medical companies [10] - The company reported a significant loss of 502 million yuan in fair value changes in 2024, which heavily impacted its net profit [10] Contractual Developments - Despite the challenges, Tigermed secured new contracts worth 10.12 billion yuan in 2024, with a net increase of 8.42 billion yuan after cancellations, indicating some resilience [10] - In Q1 2025, the net new contract amount exceeded 2 billion yuan, reflecting a 20% year-on-year growth, primarily driven by demand from multinational pharmaceutical companies [11] Expansion Efforts - Tigermed has also completed the acquisition of Japanese CRO Medical Edge to accelerate its overseas expansion [12] - The effectiveness of these measures in mitigating the impact of investment volatility remains uncertain [12]